救济治疗机构计划结束SEC的报告义务,削减成本,同时保留其在瑞士和美国的股份。 Relief Therapeutics plans to end its SEC reporting duties to cut costs, while keeping its shares listed in Switzerland and U.S.

瑞士生物制药公司救济治疗公司计划于2024年12月17日向SEC提交表格15F,以结束SEC在1934年《证券交易法》之下的登记和报告义务。 Relief Therapeutics, a Swiss biopharmaceutical firm, plans to file a Form 15F with the SEC on December 17, 2024, to end its SEC registration and reporting duties under the Securities Exchange Act of 1934. 这一举措旨在降低遵约成本,保持战略目标的灵活性。 This move aims to reduce compliance costs and maintain flexibility for strategic goals. 该公司将将其股份保留在美国的第6期瑞士交易所及其ADR方案上,而OTCQB上仍然有股份。 The company will keep its shares listed on the SIX Swiss Exchange and its ADR program in the U.S., with shares still quoted on the OTCQB. 包括年度20-F和6-K报告在内的SEC报告义务在提交后将暂停。 SEC reporting obligations, including annual 20-F and 6-K reports, will be suspended after filing.